Loading…
Relmada Therapeutics Inc Is A Clinical-Stage, Publicly Traded Biotechnology Company Focused On The Development Of Ndv-01 And Sepranolone. Ndv-01 Is A Novel, Controlled-Release Intravesical Formulation Of Gemcitabine And Docetaxel. Ndv-01 Is Currently In A Phase 2 Clinical Trial In Isreal To Assess Its Safety And Efficacy In Patients With Aggressive Forms Of Non-Muscle Invasive Bladder Cancer (Nmibc). Sepranolone Is A Novel Neurosteroid Epimer Of Allopregnanolone. Sepranolone Is Being Developed For The Potential Treatment Of Prader-Willi Syndrome, Tourette Syndrome, Excessive Tremor And Other Diseases Related To Excessive Gabaergic Activity.